Physician profile
Amina Ahmed
NPI 1154372068
$1,099,075.33
in general payments reported to CMS, 2019-2025
15 companies · $274K in 2025
The $274K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $58K · 2021: $41K · 2022: $153K · 2023: $174K · 2024: $257K · 2025: $274K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $369K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $195K · Consulting Fee: $69K · Travel and Lodging: $61K · Food and Beverage: $10K · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $369,028.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $195,460.00 |
| Consulting Fee | $69,012.75 |
| Travel and Lodging | $60,921.48 |
| Food and Beverage | $10,490.94 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $394,697.56 | 2020-2025 | |
| Glaxosmithkline, LLC. | $376,435.91 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $132,722.94 | 2019 | |
| Abbvie INC. | $98,627.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57,471.48 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $24,969.58 | 2023-2025 | Lynparza |
| Immunogen, INC. | $12,001.05 | 2023-2024 | Elahere, Elahere |
| Intuitive Surgical, INC. | $1,570.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $183.07 | 2025 | |
| Siemens Medical Solutions USA, INC. | $132.16 | 2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.40 | 2020-2022 | |
| Mindray Ds USA, INC. | $71.58 | 2021 | |
| Tempus Ai, INC | $70.91 | 2024 | Tempus Pixel |
| Genentech USA, INC. | $14.29 | 2019 | |
| Avion Pharmaceuticals | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.